About Us
At the Forefront of Developing
Novel Apoptosis Targeting Therapies
Ascentage Pharma (6855.HK) is a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. The company focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited.
Ascentage Pharma has built a pipeline of eight clinical drug candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company is conducting more than 30 Phase I/II clinical trials to evaluate the eight drug candidates in the US, Australia, and China.
Founders have been dedicated to apoptosis targeting drug innovation
for one decade
Company Culture
Mission
To discovery and development of innovative first- and best-in-class therapies to address unmet medical needs globally.
Vision
To become a fully integrated globally-focused biotechnology company.
Value
Patients First
Innovation-Driven
Science-Based
Founded in 2009,
Ascentage Pharma is headquartered in Suzhou, China
